References
- Barry AL, Fuchs PC, Allen SD, Brown SD, Jorgensen JH, Tenover FC. In-vitro susceptibility of Streptococcus pneu-moniae to the d- and 1-isomers of ofloxacin: interpretive crite-ria and quality control limits. J Antimicrob Chemother 1996; 37: 365–369.
- Biedenbach DJ, Jones RN. The comparative antimicro-bial activity of levofloxacin tested against 350 clinical isolates of streptococci. Diagn Microbiol Infect Dis 1996; 25: 47–51.
- Klugman KP, Capper T, Bryskier A. In vitro suscepti-bility of penicillin-resistant Streptococcus pneumoniae to lev-ofloxacin, selection of resistant mutants, and time-kill synergy studies of levofloxacin combined with vancomycin, teicoplanin, fusidic acid, and rifampin. Antimicrob Agents Chemother 1996; 40: 2802–2804.
- Plouffe JF. Levofloxacin in vitro activity against bac-teremic isolates of Streptococcus pneumoniae. Diagn Microbiol Infect Dis 1996; 25: 43–45.
- Visalli MA, Jacobs MR, Appelbaum PC. MIC and time-kill study of activities of DU-6859a, ciprofloxacin, lev-ofloxacin, sparfloxacin, cefotaxime, imipenem, and van-comycin against nine penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 1996; 40: 362–366.
- National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bac-teria that grow aerobically. Approved standard M 7-A4, NCCLS 1997; Wayne PA, USA.
- National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents. Proposed guideline M 26-P, NCCLS 1987; Wayne PA, USA.
- Wise R. Comparative penetration of selected fluoro-quinolones into respiratory tract fluids and tissues. Am J Med 1991; 91 (6A):675-705.
- Markus A, Isert D, Klesel N, Seibert G. Killing activity of levofloxacin and ciprofloxacin against Streptococcus pneu-moniae in vitro and in vivo. Abstract #E30, 35th ICAAC San Francisco CA, USA, Sept 17-20, 1995.
- Wise R, Child J, Mortiboy D, Chow AT. An open-label, crossover study of the pharmacokinetics and tissue penetration of two dose regimes of levofloxacin. Abstract #A54, 35th ICAAC San Francisco CA, USA, Sept. 17-20, 1995.